Funding for this research was provided by:
Muscular Dystrophy Association (577668)
ALS Therapy Alliance
Amyotrophic Lateral Sclerosis Association (14-LGCA-181)
Fondation Thierry Latran
Fonds Wetenschappelijk Onderzoek
Agentschap voor Innovatie door Wetenschap en Technologie
Fund for Scientific Research Flanders (G.0431.12N and G.0440.12N)
Interuniversity Attraction Poles Programme (P7/16)
European Community's Health Seventh Framework Programme (FP7/2007-2013)
Opening the Future - KU Leuven
Een Hart voor ALS
Laevers fund for ALS research
Finnish Cultural foundation
Received: 30 April 2019
Accepted: 12 June 2019
First Online: 5 July 2019
Ethics approval and consent to participate
: All animal experiments were approved by the ethical committee of the KU Leuven, Belgium (P055–2014) and comply with the current laws of Belgium.
: Not applicable.
: MJ is a shareholder of Acetylon Pharmaceuticals, a subsidiary of Celgene. The other authors declare that they have no competing interests.